Travere Therapeutics financials
$59.99−2.57%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $169.6M | $127.2M | $129.7M | $164.9M | $114.4M | $81.7M | $74.8M | $62.9M | $54.1M | $41.4M | $45.1M | $37.1M |
| Gross profit | $167.4M | $125.2M | $127.1M | $163.3M | $112.9M | $77.1M | $72.2M | $61.3M | $52.1M | -$25.3M | $40.5M | $35.8M |
| Gross margin | 98.7% | 98.5% | 98.0% | 99.0% | 98.7% | 94.3% | 96.6% | 97.4% | 96.2% | −61.2% | 89.9% | 96.5% |
| Operating income | $4.0M | -$36.9M | -$32.4M | $24.9M | -$12.7M | -$42.7M | -$60.7M | -$56.1M | -$67.7M | -$139.2M | -$94.2M | -$92.6M |
| Net income | -$34.8M | -$37.1M | $2.7M | $25.7M | -$12.8M | -$41.2M | -$60.3M | -$54.8M | -$70.4M | -$136.1M | -$90.2M | $150.7M |
| Net margin | −20.5% | −29.2% | 2.1% | 15.6% | −11.1% | −50.4% | −80.6% | −87.1% | −130.1% | −328.9% | −200.1% | 406.3% |
| Diluted EPS | $-0.37 | $-0.40 | $0.04 | $0.28 | $-0.14 | $-0.47 | $-0.72 | $-0.70 | $-0.91 | $-1.76 | $-1.18 | $1.97 |
| EBITDA | $8.2M | -$11.7M | -$14.3M | $40.7M | $1.4M | -$29.9M | -$47.2M | -$44.8M | -$56.7M | -$129.1M | -$82.8M | -$81.1M |
| Operating cash flow | $58.1M | -$40.4M | $60.7M | $14.3M | $5.0M | -$42.2M | -$35.7M | -$42.5M | -$40.2M | -$119.0M | -$70.5M | -$59.1M |
| Free cash flow | $58.1M | -$40.4M | $60.3M | $14.2M | $5.0M | -$42.2M | -$100.6M | -$42.5M | -$40.3M | -$119.0M | -$71.1M | -$59.1M |
| Diluted shares | 93.5M | 91.9M | 76.9M | 102.6M | 88.9M | 88.4M | 83.1M | 77.8M | 77.5M | 77.1M | 76.6M | 76.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $117.7M | $78.4M | $93.0M | $110.9M | $75.2M | $61.9M |
| Short-term investments | $371.4M | $186.3M | $229.8M | $143.6M | $244.4M | $260.3M |
| Total debt | $602.8M | $312.1M | $311.7M | $311.4M | $379.9M | $379.4M |
| Total assets | $799.4M | $555.2M | $605.2M | $538.6M | $555.3M | $548.8M |
| Total liabilities | $774.8M | $456.5M | $490.4M | $465.0M | $522.6M | $516.0M |
| Shareholders' equity | $24.5M | $98.7M | $114.8M | $73.6M | $32.7M | $32.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology